Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (cholangiocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: istaroxime, digoxin, acetyldigitoxin +3 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 121 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15634
Sealed predictions
- FXYD2 in dopamine neurons, braak-0.13 (p 0.732) → -0.39 (p 0.299)receipt 15640
Swarm cases
receipt 15640: FXYD2 in dopamine neurons, braak
- power
- full sample -0.33 (p 0.185, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.170, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.41 (p 0.091, n 18). could be the mix.
- skeptic
- leave-one-out range -0.48 to -0.24, sign flips 0; without severely affected donors -0.33 (p 0.185, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FXYD2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts